APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adult Preventable Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Adult Preventable Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025199 pages

Choose your research edition.

Industry ResearchAdult Preventable Vaccines Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Adult Preventable Vaccines Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Adult Preventable Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adult Preventable Vaccines Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Adult Preventable Vaccines Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Adult Preventable Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Adult Preventable Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Adult Preventable Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Adult Preventable Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Adult Preventable Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Adult Preventable Vaccines include Sanofi Pasteur, Johnson & Johnson (Janssen), Pfizer Inc., GlaxoSmithKline plc (GSK), Sinovac Biotech, Sinopharm Group Co.,, Serum Institute of India Pvt., Novavax, Inc. and Moderna, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Adult Preventable Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Adult Preventable Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Adult Preventable Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Adult Preventable Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Adult Preventable Vaccines Segment by Company

Sanofi Pasteur

Johnson & Johnson (Janssen)

Pfizer Inc.

GlaxoSmithKline plc (GSK)

Sinovac Biotech

Sinopharm Group Co.,

Serum Institute of India Pvt.

Novavax, Inc.

Moderna, Inc.

Merck & Co., Inc.

Emergent BioSolutions Inc.

Daiichi Sankyo Company

CSL Limited (Seqirus)

Bharat Biotech International

AstraZeneca plc

Adult Preventable Vaccines Segment by Type

Viral Vector Vaccines

Peptide Vaccines

Inactivated Vaccines

Subunit Vaccines

Mrna Vaccines

Adult Preventable Vaccines Segment by Application

Prevent Herpes Zoster

Prevent Pneumococcal Infection

Prevent Influenza

Prevent Human Papillomavirus (Hpv)

Prevent Hepatitis B

Other

Adult Preventable Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adult Preventable Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adult Preventable Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adult Preventable Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Adult Preventable Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Adult Preventable Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Adult Preventable Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Adult Preventable Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Adult Preventable Vaccines Industry Trends Table 2. Adult Preventable Vaccines Industry Drivers Table 3. Adult Preventable Vaccines Industry Opportunities and Challenges Table 4. Adult Preventable Vaccines Industry Restraints Table 5. Global Adult Preventable Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Adult Preventable Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Adult Preventable Vaccines Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Adult Preventable Vaccines Sales Market Share by Manufacturers Table 9. Global Adult Preventable Vaccines Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Adult Preventable Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Adult Preventable Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Adult Preventable Vaccines Manufacturers, Product Type & Application Table 13. Global Adult Preventable Vaccines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Adult Preventable Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Viral Vector Vaccines Table 17. Major Manufacturers of Peptide Vaccines Table 18. Major Manufacturers of Inactivated Vaccines Table 19. Major Manufacturers of Subunit Vaccines Table 20. Major Manufacturers of Mrna Vaccines Table 21. Global Adult Preventable Vaccines Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Adult Preventable Vaccines Sales by Type (2021-2026) & (K Units) Table 23. Global Adult Preventable Vaccines Sales by Type (2027-2032) & (K Units) Table 24. Global Adult Preventable Vaccines Sales Market Share by Type (2021-2026) Table 25. Global Adult Preventable Vaccines Sales Market Share by Type (2027-2032) Table 26. Global Adult Preventable Vaccines Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Adult Preventable Vaccines Revenue by Type (2021-2026) & (K Units) Table 28. Global Adult Preventable Vaccines Revenue by Type (2027-2032) & (K Units) Table 29. Global Adult Preventable Vaccines Revenue Market Share by Type (2021-2026) Table 30. Global Adult Preventable Vaccines Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Prevent Herpes Zoster Table 32. Major Manufacturers of Prevent Pneumococcal Infection Table 33. Major Manufacturers of Prevent Influenza Table 34. Major Manufacturers of Prevent Human Papillomavirus (Hpv) Table 35. Major Manufacturers of Prevent Hepatitis B Table 36. Major Manufacturers of Other Table 37. Global Adult Preventable Vaccines Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Adult Preventable Vaccines Sales by Application (2021-2026) & (K Units) Table 39. Global Adult Preventable Vaccines Sales by Application (2027-2032) & (K Units) Table 40. Global Adult Preventable Vaccines Sales Market Share by Application (2021-2026) Table 41. Global Adult Preventable Vaccines Sales Market Share by Application (2027-2032) Table 42. Global Adult Preventable Vaccines Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 43. Global Adult Preventable Vaccines Revenue by Application (2021-2026) & (K Units) Table 44. Global Adult Preventable Vaccines Revenue by Application (2027-2032) & (K Units) Table 45. Global Adult Preventable Vaccines Revenue Market Share by Application (2021-2026) Table 46. Global Adult Preventable Vaccines Revenue Market Share by Application (2027-2032) Table 47. Global Adult Preventable Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Adult Preventable Vaccines Sales by Region (2021-2026) & (K Units) Table 49. Global Adult Preventable Vaccines Sales Market Share by Region (2021-2026) Table 50. Global Adult Preventable Vaccines Sales Forecasted by Region (2027-2032) & (K Units) Table 51. Global Adult Preventable Vaccines Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Adult Preventable Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. North America Adult Preventable Vaccines Sales by Country (2021-2026) & (K Units) Table 54. North America Adult Preventable Vaccines Sales by Country (2027-2032) & (K Units) Table 55. Europe Adult Preventable Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Europe Adult Preventable Vaccines Sales by Country (2021-2026) & (K Units) Table 57. Europe Adult Preventable Vaccines Sales by Country (2027-2032) & (K Units) Table 58. Asia Pacific Adult Preventable Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. Asia Pacific Adult Preventable Vaccines Sales by Country (2021-2026) & (K Units) Table 60. Asia Pacific Adult Preventable Vaccines Sales by Country (2027-2032) & (K Units) Table 61. South America, Middle East and Africa Adult Preventable Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 62. South America, Middle East and Africa Adult Preventable Vaccines Sales by Country (2021-2026) & (K Units) Table 63. South America, Middle East and Africa Adult Preventable Vaccines Sales by Country (2027-2032) & (K Units) Table 64. Global Adult Preventable Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Adult Preventable Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Adult Preventable Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Adult Preventable Vaccines Revenue Market Share by Region (2021-2026) Table 68. Global Adult Preventable Vaccines Revenue Market Share by Region (2027-2032) Table 69. Sanofi Pasteur Company Information Table 70. Sanofi Pasteur Business Overview Table 71. Sanofi Pasteur Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sanofi Pasteur Adult Preventable Vaccines Product Portfolio Table 73. Sanofi Pasteur Recent Development Table 74. Johnson & Johnson (Janssen) Company Information Table 75. Johnson & Johnson (Janssen) Business Overview Table 76. Johnson & Johnson (Janssen) Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Johnson & Johnson (Janssen) Adult Preventable Vaccines Product Portfolio Table 78. Johnson & Johnson (Janssen) Recent Development Table 79. Pfizer Inc. Company Information Table 80. Pfizer Inc. Business Overview Table 81. Pfizer Inc. Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pfizer Inc. Adult Preventable Vaccines Product Portfolio Table 83. Pfizer Inc. Recent Development Table 84. GlaxoSmithKline plc (GSK) Company Information Table 85. GlaxoSmithKline plc (GSK) Business Overview Table 86. GlaxoSmithKline plc (GSK) Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. GlaxoSmithKline plc (GSK) Adult Preventable Vaccines Product Portfolio Table 88. GlaxoSmithKline plc (GSK) Recent Development Table 89. Sinovac Biotech Company Information Table 90. Sinovac Biotech Business Overview Table 91. Sinovac Biotech Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Sinovac Biotech Adult Preventable Vaccines Product Portfolio Table 93. Sinovac Biotech Recent Development Table 94. Sinopharm Group Co., Company Information Table 95. Sinopharm Group Co., Business Overview Table 96. Sinopharm Group Co., Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Sinopharm Group Co., Adult Preventable Vaccines Product Portfolio Table 98. Sinopharm Group Co., Recent Development Table 99. Serum Institute of India Pvt. Company Information Table 100. Serum Institute of India Pvt. Business Overview Table 101. Serum Institute of India Pvt. Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Serum Institute of India Pvt. Adult Preventable Vaccines Product Portfolio Table 103. Serum Institute of India Pvt. Recent Development Table 104. Novavax, Inc. Company Information Table 105. Novavax, Inc. Business Overview Table 106. Novavax, Inc. Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Novavax, Inc. Adult Preventable Vaccines Product Portfolio Table 108. Novavax, Inc. Recent Development Table 109. Moderna, Inc. Company Information Table 110. Moderna, Inc. Business Overview Table 111. Moderna, Inc. Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Moderna, Inc. Adult Preventable Vaccines Product Portfolio Table 113. Moderna, Inc. Recent Development Table 114. Merck & Co., Inc. Company Information Table 115. Merck & Co., Inc. Business Overview Table 116. Merck & Co., Inc. Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Merck & Co., Inc. Adult Preventable Vaccines Product Portfolio Table 118. Merck & Co., Inc. Recent Development Table 119. Emergent BioSolutions Inc. Company Information Table 120. Emergent BioSolutions Inc. Business Overview Table 121. Emergent BioSolutions Inc. Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Emergent BioSolutions Inc. Adult Preventable Vaccines Product Portfolio Table 123. Emergent BioSolutions Inc. Recent Development Table 124. Daiichi Sankyo Company Company Information Table 125. Daiichi Sankyo Company Business Overview Table 126. Daiichi Sankyo Company Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Daiichi Sankyo Company Adult Preventable Vaccines Product Portfolio Table 128. Daiichi Sankyo Company Recent Development Table 129. CSL Limited (Seqirus) Company Information Table 130. CSL Limited (Seqirus) Business Overview Table 131. CSL Limited (Seqirus) Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. CSL Limited (Seqirus) Adult Preventable Vaccines Product Portfolio Table 133. CSL Limited (Seqirus) Recent Development Table 134. Bharat Biotech International Company Information Table 135. Bharat Biotech International Business Overview Table 136. Bharat Biotech International Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Bharat Biotech International Adult Preventable Vaccines Product Portfolio Table 138. Bharat Biotech International Recent Development Table 139. AstraZeneca plc Company Information Table 140. AstraZeneca plc Business Overview Table 141. AstraZeneca plc Adult Preventable Vaccines Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. AstraZeneca plc Adult Preventable Vaccines Product Portfolio Table 143. AstraZeneca plc Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. Adult Preventable Vaccines Distributors List Table 147. Adult Preventable Vaccines Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Adult Preventable Vaccines Product Image Figure 2. Global Adult Preventable Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adult Preventable Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Adult Preventable Vaccines Sales (2021-2032) & (K Units) Figure 5. Global Adult Preventable Vaccines Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Adult Preventable Vaccines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Viral Vector Vaccines Image Figure 9. Peptide Vaccines Image Figure 10. Inactivated Vaccines Image Figure 11. Subunit Vaccines Image Figure 12. Mrna Vaccines Image Figure 13. Global Adult Preventable Vaccines Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Adult Preventable Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Adult Preventable Vaccines Sales Market Share by Type (2021-2032) Figure 16. Global Adult Preventable Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Adult Preventable Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Adult Preventable Vaccines Revenue Market Share by Type (2021-2032) Figure 19. Prevent Herpes Zoster Image Figure 20. Prevent Pneumococcal Infection Image Figure 21. Prevent Influenza Image Figure 22. Prevent Human Papillomavirus (Hpv) Image Figure 23. Prevent Hepatitis B Image Figure 24. Other Image Figure 25. Global Adult Preventable Vaccines Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Adult Preventable Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Adult Preventable Vaccines Sales Market Share by Application (2021-2032) Figure 28. Global Adult Preventable Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 29. Global Adult Preventable Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Adult Preventable Vaccines Revenue Market Share by Application (2021-2032) Figure 31. North America Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 32. North America Adult Preventable Vaccines Sales Market Share by Country (2021-2032) Figure 33. U.S. Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Canada Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Mexico Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Europe Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Europe Adult Preventable Vaccines Sales Market Share by Country (2021-2032) Figure 38. Germany Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 39. France Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 40. U.K. Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Italy Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Netherlands Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Asia Pacific Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Asia Pacific Adult Preventable Vaccines Sales Market Share by Country (2021-2032) Figure 45. China Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Japan Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Korea Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Southeast Asia Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 49. India Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Australia Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South America, Middle East and Africa Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South America, Middle East and Africa Adult Preventable Vaccines Sales Market Share by Country (2021-2032) Figure 53. Brazil Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 54. South Africa Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Saudi Arabia Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Turkey Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Argentina Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 58. UAE Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Egypt Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 60. Chile Adult Preventable Vaccines Sales and Growth Rate (2021-2032) & (K Units) Figure 61. Global Adult Preventable Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Adult Preventable Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Adult Preventable Vaccines Revenue (2021-2032) & (US$ Million) Figure 64. North America Adult Preventable Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Adult Preventable Vaccines Revenue (2021-2032) & (US$ Million) Figure 66. Europe Adult Preventable Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Adult Preventable Vaccines Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Adult Preventable Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Adult Preventable Vaccines Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Adult Preventable Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Adult Preventable Vaccines Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Adult Preventable Vaccines Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Viral Vector Vaccines
  • Peptide Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • Mrna Vaccines
Applications
  • Prevent Herpes Zoster
  • Prevent Pneumococcal Infection
  • Prevent Influenza
  • Prevent Human Papillomavirus (Hpv)
  • Prevent Hepatitis B
  • Other
Companies covered
  • Sanofi Pasteur
  • Johnson & Johnson (Janssen)
  • Pfizer Inc.
  • GlaxoSmithKline plc (GSK)
  • Sinovac Biotech
  • Sinopharm Group Co.,
  • Serum Institute of India Pvt.
  • Novavax, Inc.
  • Moderna, Inc.
  • Merck & Co., Inc.
  • Emergent BioSolutions Inc.
  • Daiichi Sankyo Company
  • CSL Limited (Seqirus)
  • Bharat Biotech International
  • AstraZeneca plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Adult Preventable Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Adult Preventable Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Adult Preventable Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Adult Preventable Vaccines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Adult Preventable Vaccines Market Dynamics
  1. 2.1 Adult Preventable Vaccines Industry Trends
  2. 2.2 Adult Preventable Vaccines Industry Drivers
  3. 2.3 Adult Preventable Vaccines Industry Opportunities and Challenges
  4. 2.4 Adult Preventable Vaccines Industry Restraints
3 Adult Preventable Vaccines Market by Manufacturers
  1. 3.1 Global Adult Preventable Vaccines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Adult Preventable Vaccines Sales by Manufacturers (2021-2026)
  3. 3.3 Global Adult Preventable Vaccines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Adult Preventable Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Adult Preventable Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Adult Preventable Vaccines Manufacturers, Product Type & Application
  7. 3.7 Global Adult Preventable Vaccines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Adult Preventable Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Adult Preventable Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Adult Preventable Vaccines Tier 1, Tier 2, and Tier 3
4 Adult Preventable Vaccines Market by Type
  1. 4.1 Adult Preventable Vaccines Type Introduction
  2. 4.1.1 Viral Vector Vaccines
  3. 4.1.2 Peptide Vaccines
  4. 4.1.3 Inactivated Vaccines
  5. 4.1.4 Subunit Vaccines
  6. 4.1.5 Mrna Vaccines
  7. 4.2 Global Adult Preventable Vaccines Sales by Type
  8. 4.2.1 Global Adult Preventable Vaccines Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Adult Preventable Vaccines Sales by Type (2021-2032)
  10. 4.2.3 Global Adult Preventable Vaccines Sales Market Share by Type (2021-2032)
  11. 4.3 Global Adult Preventable Vaccines Revenue by Type
  12. 4.3.1 Global Adult Preventable Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Adult Preventable Vaccines Revenue by Type (2021-2032)
  14. 4.3.3 Global Adult Preventable Vaccines Revenue Market Share by Type (2021-2032)
5 Adult Preventable Vaccines Market by Application
  1. 5.1 Adult Preventable Vaccines Application Introduction
  2. 5.1.1 Prevent Herpes Zoster
  3. 5.1.2 Prevent Pneumococcal Infection
  4. 5.1.3 Prevent Influenza
  5. 5.1.4 Prevent Human Papillomavirus (Hpv)
  6. 5.1.5 Prevent Hepatitis B
  7. 5.1.6 Other
  8. 5.2 Global Adult Preventable Vaccines Sales by Application
  9. 5.2.1 Global Adult Preventable Vaccines Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Adult Preventable Vaccines Sales by Application (2021-2032)
  11. 5.2.3 Global Adult Preventable Vaccines Sales Market Share by Application (2021-2032)
  12. 5.3 Global Adult Preventable Vaccines Revenue by Application
  13. 5.3.1 Global Adult Preventable Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Adult Preventable Vaccines Revenue by Application (2021-2032)
  15. 5.3.3 Global Adult Preventable Vaccines Revenue Market Share by Application (2021-2032)
6 Global Adult Preventable Vaccines Sales by Region
  1. 6.1 Global Adult Preventable Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Adult Preventable Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Adult Preventable Vaccines Sales by Region (2021-2026)
  4. 6.2.2 Global Adult Preventable Vaccines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Adult Preventable Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Adult Preventable Vaccines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Adult Preventable Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Adult Preventable Vaccines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Adult Preventable Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Adult Preventable Vaccines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Adult Preventable Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Adult Preventable Vaccines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Adult Preventable Vaccines Revenue by Region
  1. 7.1 Global Adult Preventable Vaccines Revenue by Region
  2. 7.1.1 Global Adult Preventable Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Adult Preventable Vaccines Revenue by Region (2021-2026)
  4. 7.1.3 Global Adult Preventable Vaccines Revenue by Region (2027-2032)
  5. 7.1.4 Global Adult Preventable Vaccines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Adult Preventable Vaccines Revenue (2021-2032)
  8. 7.2.2 North America Adult Preventable Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Adult Preventable Vaccines Revenue (2021-2032)
  11. 7.3.2 Europe Adult Preventable Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Adult Preventable Vaccines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Adult Preventable Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Adult Preventable Vaccines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Adult Preventable Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi Pasteur
  2. 8.1.1 Sanofi Pasteur Company Information
  3. 8.1.2 Sanofi Pasteur Business Overview
  4. 8.1.3 Sanofi Pasteur Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Pasteur Adult Preventable Vaccines Product Portfolio
  6. 8.1.5 Sanofi Pasteur Recent Developments
  7. 8.2 Johnson & Johnson (Janssen)
  8. 8.2.1 Johnson & Johnson (Janssen) Company Information
  9. 8.2.2 Johnson & Johnson (Janssen) Business Overview
  10. 8.2.3 Johnson & Johnson (Janssen) Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson (Janssen) Adult Preventable Vaccines Product Portfolio
  12. 8.2.5 Johnson & Johnson (Janssen) Recent Developments
  13. 8.3 Pfizer Inc.
  14. 8.3.1 Pfizer Inc. Company Information
  15. 8.3.2 Pfizer Inc. Business Overview
  16. 8.3.3 Pfizer Inc. Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Inc. Adult Preventable Vaccines Product Portfolio
  18. 8.3.5 Pfizer Inc. Recent Developments
  19. 8.4 GlaxoSmithKline plc (GSK)
  20. 8.4.1 GlaxoSmithKline plc (GSK) Company Information
  21. 8.4.2 GlaxoSmithKline plc (GSK) Business Overview
  22. 8.4.3 GlaxoSmithKline plc (GSK) Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline plc (GSK) Adult Preventable Vaccines Product Portfolio
  24. 8.4.5 GlaxoSmithKline plc (GSK) Recent Developments
  25. 8.5 Sinovac Biotech
  26. 8.5.1 Sinovac Biotech Company Information
  27. 8.5.2 Sinovac Biotech Business Overview
  28. 8.5.3 Sinovac Biotech Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sinovac Biotech Adult Preventable Vaccines Product Portfolio
  30. 8.5.5 Sinovac Biotech Recent Developments
  31. 8.6 Sinopharm Group Co.,
  32. 8.6.1 Sinopharm Group Co., Company Information
  33. 8.6.2 Sinopharm Group Co., Business Overview
  34. 8.6.3 Sinopharm Group Co., Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sinopharm Group Co., Adult Preventable Vaccines Product Portfolio
  36. 8.6.5 Sinopharm Group Co., Recent Developments
  37. 8.7 Serum Institute of India Pvt.
  38. 8.7.1 Serum Institute of India Pvt. Company Information
  39. 8.7.2 Serum Institute of India Pvt. Business Overview
  40. 8.7.3 Serum Institute of India Pvt. Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Serum Institute of India Pvt. Adult Preventable Vaccines Product Portfolio
  42. 8.7.5 Serum Institute of India Pvt. Recent Developments
  43. 8.8 Novavax, Inc.
  44. 8.8.1 Novavax, Inc. Company Information
  45. 8.8.2 Novavax, Inc. Business Overview
  46. 8.8.3 Novavax, Inc. Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Novavax, Inc. Adult Preventable Vaccines Product Portfolio
  48. 8.8.5 Novavax, Inc. Recent Developments
  49. 8.9 Moderna, Inc.
  50. 8.9.1 Moderna, Inc. Company Information
  51. 8.9.2 Moderna, Inc. Business Overview
  52. 8.9.3 Moderna, Inc. Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Moderna, Inc. Adult Preventable Vaccines Product Portfolio
  54. 8.9.5 Moderna, Inc. Recent Developments
  55. 8.10 Merck & Co., Inc.
  56. 8.10.1 Merck & Co., Inc. Company Information
  57. 8.10.2 Merck & Co., Inc. Business Overview
  58. 8.10.3 Merck & Co., Inc. Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Merck & Co., Inc. Adult Preventable Vaccines Product Portfolio
  60. 8.10.5 Merck & Co., Inc. Recent Developments
  61. 8.11 Emergent BioSolutions Inc.
  62. 8.11.1 Emergent BioSolutions Inc. Company Information
  63. 8.11.2 Emergent BioSolutions Inc. Business Overview
  64. 8.11.3 Emergent BioSolutions Inc. Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Emergent BioSolutions Inc. Adult Preventable Vaccines Product Portfolio
  66. 8.11.5 Emergent BioSolutions Inc. Recent Developments
  67. 8.12 Daiichi Sankyo Company
  68. 8.12.1 Daiichi Sankyo Company Company Information
  69. 8.12.2 Daiichi Sankyo Company Business Overview
  70. 8.12.3 Daiichi Sankyo Company Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Daiichi Sankyo Company Adult Preventable Vaccines Product Portfolio
  72. 8.12.5 Daiichi Sankyo Company Recent Developments
  73. 8.13 CSL Limited (Seqirus)
  74. 8.13.1 CSL Limited (Seqirus) Company Information
  75. 8.13.2 CSL Limited (Seqirus) Business Overview
  76. 8.13.3 CSL Limited (Seqirus) Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 CSL Limited (Seqirus) Adult Preventable Vaccines Product Portfolio
  78. 8.13.5 CSL Limited (Seqirus) Recent Developments
  79. 8.14 Bharat Biotech International
  80. 8.14.1 Bharat Biotech International Company Information
  81. 8.14.2 Bharat Biotech International Business Overview
  82. 8.14.3 Bharat Biotech International Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bharat Biotech International Adult Preventable Vaccines Product Portfolio
  84. 8.14.5 Bharat Biotech International Recent Developments
  85. 8.15 AstraZeneca plc
  86. 8.15.1 AstraZeneca plc Company Information
  87. 8.15.2 AstraZeneca plc Business Overview
  88. 8.15.3 AstraZeneca plc Adult Preventable Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AstraZeneca plc Adult Preventable Vaccines Product Portfolio
  90. 8.15.5 AstraZeneca plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Adult Preventable Vaccines Value Chain Analysis
  2. 9.1.1 Adult Preventable Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Adult Preventable Vaccines Production Mode & Process
  6. 9.2 Adult Preventable Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Adult Preventable Vaccines Distributors
  9. 9.2.3 Adult Preventable Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst